Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

October 6, 2022

Study Completion Date

October 6, 2022

Conditions
Lymphoid LeukemiaMyeloid LeukemiaMonocytic LeukemiaMyelodysplasia
Interventions
DRUG

Intravenous (IV) and oral Vitamin C

"Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180"

Trial Locations (1)

23298

Virginia Commonwealth University/ Massey Cancer Center, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER

NCT03613727 - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | Biotech Hunter | Biotech Hunter